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Abstract: Objective: The pineal hormone melatonin plays a crucial role in immunomodulation, mainly by effecting T 
cells. The aims of the present study were to compare the melatonin levels in patients with Familial Mediterranean Fever 
(FMF) and healthy controls and to find out if it associates with interferon(IFN) and interleukin(IL)-10. 
Materials and  Methodology:  Twenty five patients with FMF and 16 healthy donors were enrolled into the study. 
Melatonin, IFN  and IL-10 measurements were assayed by using enzyme immunoassay (EIA) method. 
Results: Serum melatonin levels at 03.30 am in both patients during attack-free phase and healthy controls were 
significantly higher than those levels of corresponding groups measured at 10.00 am. The melatonin levels at 03.30 and 
10.00 am in patients during attack-free phase were higher than those levels measured in healthy controls at the same time 
points. IFN and IL-10 did not show any day and night rhythm in both patients and healthy controls. In addition, there 
was no association among day and night levels of melatonin, IFN and IL-10. 
Conclusions: We conclude that melatonin may play a role in FMF pathogenesis. However, its modulatory effect on 
immune response most likely does not depend on T cells. Further comprehensive studies should be performed in order to 
reveal the role of melatonin in the pathogenesis of this disease. 
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INTRODUCTION 
  Familial Mediterranean Fever (FMF) is a systemic 
relapsing autoinflammatory disorder occurring in populat-
ions originating from the Mediterranean basin, mainly Turks, 
Levantine Arabs, Sephardic Jews, Druze and Armenians [1, 
2]. The most characteristic clinical manifestation of the 
disease is periodic attacks of fever accompanied by serosal 
membrane inflammation at the affected sites such as 
peritoneum, pleura or synovium, with a massive influx of 
polymorphonuclear neutrophils [3]. The gene causing FMF, 
MEFV, is localized to chromosome 16p13, and its mutations 
cause the autoinflammatory phenotype of FMF [4]. 
  Previously, some immunological abnormalities including 
impaired production of proinflammatory cytokines such as 
tumor necrosis factor(TNF), interleukin(IL)-1 and IL-6 
have been reported in FMF [5-9]. These findings support that 
FMF is a disease of the innate immune system. However, the 
two branches of the adaptive immune system, B cells and T 
cells, seem to contribute to the disease pathogenesis by 
mainly their secretory products [9-11]. 
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  It is well known that T helper (Th) cell populations are 
subdivided into two different types based on the cytokines they 
secrete [12, 13]. Th1 type cells heavily produce inflammatory 
cytokine interferon(IFN), while Th2 type cells heavily produce 
anti-inflammatory cytokine IL-4. It was previously reported that 
Th1/Th2 balance may exhibit diurnal rhythmicity in healthy 
humans, and melatonin may regulate diurnal variation in 
IFN/IL-10 ratio [14]. The pineal hormone melatonin is 
involved in the regulation of circadian rhythm, and its 
production is highest at night. It was shown that melatonin has 
specific binding sites on both Th1 and Th2 cells, which enhance 
Th cell activity by increasing IL-2 production [15, 16]. Melato-
nin also stimulates IL-12 production by monocytes driving T 
cell differentiation toward the Th1 type and causing an increase 
in IFN production [17]. 
  We previously showed that the CD4+ Th cells are 
abnormally activated in patients with FMF in both the attack 
and the attack-free phases, and that decreased IL-10 levels may 
create a tendency to perpetuate subclinical immune activation in 
the attack phase [18]. Therefore, in the present study, we aimed 
to determine whether serum melatonin concentrations are 
associated with FMF and serum IFN and IL-10 levels. 
MATERIALS AND METHODOLOGY 
Patients 
  Twenty five patients with FMF (20 male, 5 female) and 
16 sex- and age-matched healthy volunteers (13 male, 3 14   The Open Rheumatology Journal, 2011, Volume 5  Musabak et al. 
female) were enrolled into the study. None of the patients 
with FMF had an immunological disorder or another 
rheumatic disease. The clinical diagnosis of FMF was based 
on the Tel-Hashomer criteria [19]. Attack-free phases 
(defined as being free of attacks for at least 3 weeks) and 
acute phases were determined based on clinical (fever, 
abdominal pain, arthritis) and laboratory findings [high 
levels of fibrinogen, white blood cell (WBC) count and 
erythrocyte sedimentation rate (ESR)]. All patients were 
evaluated during both the attack-free and the attack phases. 
The immunological parameters of patients with active 
clinical presentations were measured within the first 48 h 
following onset of the attack. This study was conducted in 
conformity to the Helsinki Declaration and approved by our 
local research ethics committee. 
  Ten milliliters of venous blood was drawn from the 
patients in attack-free phase and healthy controls at 03.30 am 
and 10.00 am and centrifuged at 3000 r.p.m. for 30 min for 
the measurements of melatonin, IFN and IL-10 levels. The 
blood was also collected from the patients in attack phase at 
10.00 am for determining the same parameters. The 
specimens were stored at -20°C until analysis. 
Laboratory Analyses 
  White blood cell count was performed using an 
automated whole blood cell counter (Cell-Dyn 1700, Abbot, 
Santa Clara, CA, USA) and the reference range was between 
3600-10 000/mm
3. The Westergreen method was used for 
ESR. Normal levels of ESR were 0–15 mm/hr for males and 
0–20 mm/hr for females. Fibrinogen levels were measured 
by a photooptic method using fibrinogen reagent (Sigma 
Diagnostics) and an Amelung AMAX 190 Plus analyzer. 
Reference range of fibrinogen levels was 200-400 mg/dl 
according to manufacturer’s instructions. All of these tests 
were measured in daytime (at 10.00 am). 
Measurements of Melatonin, IFN and IL-10 
  The levels of serum melatonin (IBL International, 
Hamburg, Germany) were measured by enzyme 
immunoassay (EIA), while IFN and IL-10 (DiaSource, 
Nivelles, Belgium) were measured by enzyme amplified 
sensitivity immunoassay (EASIA). Absorbance readings 
were carried out on Alisei Quality System (SEAC Radim 
Group, Pomezia, Italy). Serum concentrations of melatonin, 
IFN and IL-10 were determined from a curve obtained with 
the standards. According to manufacturer instructions, the 
detection limits of kits were 1.6 pg/ml for melatonin and IL-
10, and 0.03 IU/ml for IFN. 
Statistical Analysis 
  All statistical analyses were performed using a computer 
software (SPSS for Windows version 11.5, SPSS Inc., 
Chicago, IL, USA). For the tests of normality, we used 
Kolmogorov-Smirnov test. Independent-Samples T test was 
used for the comparisons of study groups with respect to age, 
body mass index (BMI), WBC counts, ESR and fibrinogen 
levels. The Friedman test was used for multiple statistical 
comparisons. The Wilcoxon test was used as a post hoc test, 
if the Friedman test is statistically significant. This test was 
also used for the comparison of two dependent groups. 
Mann-Whitney U test and Chi-square tests were respectively 
used to compare the median values of melatonin and the 
percentages of detectable IFN levels or gender difference in 
the study groups. To investigate the relations among the 
variables, we used Pearson or Spearman’s rank correlation 
test, whichever was appropriated. A p value < 0.05 was 
considered to be statistically significant. 
RESULTS 
  The general characteristics and main laboratory 
parameters of the study groups were summarized in Table 1. 
Age, gender and body mass index (BMI) in the patients with 
FMF and healthy controls were not different from each 
other. In an attack phase, all of the 25 patients with FMF had 
abdominal pain (100%), 4 (16%) had pleuritic chest pain and 
4 (16%) had arthritis/arthralgia. Seven of the 25 patients 
(28%) had a family history of FMF. Except for 6 newly 
diagnosed patients, all of the other 19 patients were on a 
continuous colchicine treatment (1–2 mg/day). WBC counts 
in 22 patients (88%), ESR in 25 patients (100%) and 
fibrinogen in 17 patients (68%) in attack phases were 
elevated above the normal ranges of these laboratory 
parameters. Body temperatures increased in all patients 
(100%) during attack phase. 
  Melatonin levels measured at 03.30 am both in patients 
with FMF in attack-free phase and healthy controls were 
Table 1.  Demographic and Main Laboratory Parameters in Patients with FMF and Healthy Controls 
 
  Patients with FMF (n=25)  Healthy Controls
 (n=16) 
Age (years)  21.3 ± 1.4  21.0 ± 1.3 
Male/Female 20/5  13/3 
BMI  23.7 ± 1.5  23.2 ± 1.8 
  in acute attack phase 
*  in atttack-free phase 
  
WBC (mm
3)  10028 ± 1997  6156 ± 1238  6518 ± 1395 
ESR (mm/hr)  39.3 ± 7.2  13.2 ± 5.1  13.3 ± 5.4 
Fibrinogen (mg/dl)  400 ± 58  347 ± 70  317 ± 58 
Body Temperature (°C)  37.7 ± 0.6  36.2 ± 0.5  36.2 ± 0.7 
The measurements were expressed in mean ± standard deviation. Comparisons between means were made by Independent Samples T test. Chi-square test was used for gender 
comparison.
* P values were lower than 0.05 in the comparisons between either the patients during attack and attack-free phases or patients during attack phase and healthy controls 
with regards to WBC, ESR, fibrinogen and body temperature. 
 These parameters were measured at 10.00 am. Melatonin in Familial Mediterranean Fever  The Open Rheumatology Journal, 2011, Volume 5   15 
higher than those measured at 10.00 am (Table 2, Fig. 1). 
While melatonin levels measured at 03.30 am in patients 
with FMF in attack-free phase were higher than those 
measured in the attack phase, there was no significant 
difference between melatonin levels at the two phases 
measured at 10.00 am. The melatonin levels of patients with 
FMF in attack-free phase both at 03.30 am and 10.00 am 
were also higher than those the levels of healthy controls 
measured at the same time points. 
 
Fig. (1). Comparison of melatonin levels at different times of the 
day in patients with FMF and healthy controls. Boxes show the 
ranges of 1st and 3rd quartiles and extreme values, with the 
horizontal bars representing median values. P-values were indicated 
with an asterix above the boxes when a level of significance < 0.05 
was reached in comparisons of study groups. 
  On the other hand, the percentage of patients with FMF 
who had detectable concentrations of IFN in the attack 
phase was higher than the percentage of patients with 
detectable concentrations of IFN in the attack-free phase at 
both 03.30 am and 10.00 am. (Table 3). No significant 
difference at 03.30 am and 10.00 am measurements between 
attack-free patients and healthy controls was observed. Only 
1 of the 25 patients was found to have detectable IL-10 
levels in attack phase. None of the patients in attack-free 
phase and none of the healthy controls had detectable IL-10 
levels at 03.30 am and 10.00 am. 
Table  3.  The Presence of IFN in Patients with FMF and 
Healthy Controls 
 
Individuals who had detectable IFN
* 
n (%)   
in Acute Attack  at 03.30 am  at 10.00 am 
Patients with FMF (n=25)  20(80)
a 13(52)
b 13(52)
c 
Healthy Controls (n=16)    12(75)  12(75) 
Comparisons between the percentages were made by chi-square test. X
2= 4.367; 
p=0.037 for a vs b and a vs c. 
*The number and percentages of patients with FMF who 
had detectable IFN at 03.30 am and 10.00 am shows the results in attack-free phase. 
 
  We didn’t find any correlation among the levels of 
melatonin, IFN and IL-10 in both patients with FMF and 
healthy controls. All these parameters were also not 
correlated with acute phase reactants such as ESR, WBC and 
fibrinogen levels. 
DISCUSSION 
  Accumulated data in the literature until now suggest that 
melatonin has dual effect on inflammation as stimulating or 
inhibiting [20, 21]. These opposite actions of melatonin 
mainly depend on polarization of naive T cells into Th1 or 
Th2 [22]. It seems that T cells are the main target of 
melatonin in mice and humans [16, 22]. In Inserra et al.’s 
study, it was shown that melatonin significantly increases 
Th1 cytokines, IL-2 and IFN-gamma, whereas significantly 
decreases Th2 cytokines, IL-6 and IL-10 in aged female 
C57BL/6 mice [23]. In contrast, Shaji et al. demonstrated 
that melatonin induces the Th2 like immune response by 
stimulating IL-4 production in mice [24]. In another study, 
inhibitory effect of melatonin on TNF production in mice 
treated with a lethal dose of lipopolysaccharide has been 
shown by Sacco et al. [25]. The inhibitory effect of 
melatonin on concanavalin A (ConA)-induced proliferative 
response of human peripheral blood lymphocytes was found 
in physiologic dose (10
-9 M) in Konakchieva et al.’s study 
[26], whereas pharmacologic doses (>0.20 mM) of 
melatonin were required to achieve inhibitory effect of 
melatonin on the proliferation of mitogen-stimulated human 
peripheral blood lymphocytes in Vijayalxmi et al.’s study 
[27]. 
  The number of studies investigating the role of melatonin 
on the immunopathogenesis of any disease is limited in the 
literature. In general, these studies were done in Th1 driven 
diseases such as rheumatoid arthritis (RA) and multiple 
sclerosis (MS). In addition, until now, melatonin has not 
been studied in any autoinflammatory diseases. Therefore, 
we compared our current study results with those of the 
studies on autoimmune diseases. We demonstrated for the 
Table 2.  Melatonin Levels in Patients with FMF and Healthy Controls 
 
Melatonin Levels (pg/ml)
* 
 
in Acute Attack  at 03.30 am  at 10.00 am 
Patients with FMF (n=25)  17.1 (7.7-32.9)
a 184.5  (55.9-354.8)
b 15.3  (4.5-133.8)
c 
Healthy Controls (n=16)    68.3 (11.3-192.3)
d 6.4  (5.1-9.8)
e 
The measurements were expressed in median (minimum-maximum). Comparisons between medians were made by Mann-Whitney U test. p<0.001 for a vs b, b vs c, a vs e, d vs e, b 
vs d, and c vs e; p=0.543 for a vs c. 
*Melatonin levels at 03.30 am and 10.00 am in patients with FMF were measured in attack-free phase. 16   The Open Rheumatology Journal, 2011, Volume 5  Musabak et al. 
first time in the current study that FMF patients had higher 
melatonin levels at night (03.30 am) and daytime (10.00 am) 
compared to those of healthy controls. However, the serum 
melatonin concentration was neither correlated with IFN 
levels, nor with IL-10 levels in FMF patients and control 
subjects. We also couldn’t find a day and night rhythm for 
IFN and IL-10 in our study groups. 
  Partially similar results were found in Sully et al.’s study 
in which melatonin serum levels at 8 pm and 8 am were 
found to be higher in RA patients than in healthy controls 
[28]. However melatonin levels at 2, 4, 6 am and 12 pm were 
not different from those of healthy controls. In addition, the 
authors proposed that the clinical symptoms of RA, such as 
morning gelling, stiffness, and swelling, which are more 
evident in the early morning, might be related to the 
immunomodulatory effects of melatonin on synovitis. Cutolo 
et al. also suggest that increased nocturnal melatonin 
production in RA patients seems to be an important factor in 
the appearance of the circadian symptoms of the disease 
[29]. Accordingly, in RA patients, proinflammatory Th1 type 
cytokine production exhibits a diurnal rhythmicity with peak 
levels during the night and early morning, when plasma 
cortisol is lowest and melatonin is highest. Haase et al. 
showed that serum melatonin levels in benign MS patients 
significantly decrease with azathioprine (AZA) treatment 
compared to untreated patients [30]. They suggest that 
immunosuppressive effect of AZA during the stabile phase 
of MS was largely due to decreasing melatonin production. 
This study also indicates that melatonin have an 
immunomodulatory effect in MS disease. 
  We could not detect any relationship between melatonin 
and the cytokines IFN and IL-10 in FMF patients. However, 
we may speculate that high levels of melatonin during night-
time and day-time in the FMF patients may contribute the 
disease pathogenesis by stimulating other immune cells. It 
was formerly reported that melatonin has an activation 
capability on monocytes, natural killer cells, and neutrophils 
[29]. Especially, the studies related to the effects of 
melatonin on neutrophil functions may help us to understand 
the role of melatonin in FMF disease which is known as a 
neutrophil-related disease [31]. 
  In conclusion, the immunoregulatory role of melatonin is 
very complex, and its mechanisms are not yet completely 
understood. Due to this striking feature, melatonin may be 
involved in immunopathogenesis of many autoimmune and 
autoinflammatory diseases. Our findings provide an 
evidence that melatonin may play a role in the 
immunopathogenesis of FMF. However, further 
comprehensive researches investigating the relationships 
between melatonin and immune response in FMF are needed 
to understand its role in the pathogenesis of this disease. 
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